Floatz logo

pnt2258

Lymphoma, Diffuse Large B-Cell

Sierra Oncology LLC - a GSK companyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

271 Active assets in the Lymphoma, Diffuse Large B-Cell cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

pnt2258 is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
Richter transformationDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →